0A2V Stock Chart & Stats
$45.59
$0.01(0.02%)
At close: 4:00 PM EDT
$45.59
$0.01(0.02%)
Day’s Range― - ―
52-Week Range$40.80 - $52.65
Previous CloseN/A
Volume12.00
Average Volume (3M)99.91K
Market Cap
$109.41B
Enterprise Value$122.96K
Total Cash (Recent Filing)$6.35B
Total Debt (Recent Filing)$23.58B
Price to Earnings (P/E)23.6
Beta0.79
Next Earnings
Oct 30, 2026EPS Estimate
1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding2,415,546,900
10 Day Avg. Volume103,389
30 Day Avg. Volume99,911
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.15
P/FCF Ratio9.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$56.00Price Target Upside22.83% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)4.93
Revenue Forecast (FY)$57.24B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthSanofi’s continued top-line expansion indicates broad product demand and commercial traction across medicines and vaccines. Growth provides a durable base for funding research, supporting scale, and absorbing competitive or reimbursement pressures.
Conservative Balance SheetModerate leverage and substantial equity give Sanofi financial flexibility to sustain R&D, invest in manufacturing, pursue partnerships, and manage regulatory setbacks without relying heavily on additional borrowing.
Expanding Specialty Product PortfolioRecent regulatory expansions improve the usability and addressable populations of Sanofi’s vaccines and specialty medicines. These approvals can strengthen market positions, support lifecycle growth, and diversify future revenue beyond mature products.
Bears Say
Operating Margin PressureFalling operating profit while revenue rises suggests higher operating costs, mix pressure, or reduced pricing leverage. If persistent, this could limit profit conversion from growth and constrain funds available for innovation.
Volatile Free Cash FlowPositive cash generation is a strength, but uneven free cash flow reduces planning visibility and makes cash conversion less dependable. Sustained volatility could complicate dividend, investment, and debt-management decisions.
Uneven Earnings And EPS DeclineThe sharp EPS decline and uneven historical earnings indicate that reported growth has not translated consistently into per-share profits. This weakens earnings predictability and increases dependence on successful products and cost control.
Sanofi News
0A2V FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest share price was $40.80 and its highest was $52.65 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $109.41B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Oct 30, 2026 which is in 62 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jul 30, 2026. The company reported $1.202 earnings per share for the quarter, beating the consensus estimate of $1.088 by $0.114.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi does not currently pay dividends.
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.63.
How many shares outstanding does Sanofi have?
Sanofi has 2,415,546,900 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $1.202 in its last earnings report, beating expectations of $1.088. Following the earnings report the stock price went down -7.971%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in GB:0A2V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanofi Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$56.00 (22.83% Upside)
$56.00 (22.83% Upside)
Blogger Sentiment
Bullish
GB:0A2V Sentiment 88%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.07%
12-Months-Change
Fundamentals
Return on Equity
5.58%
Trailing 12-Months
Asset Growth
0.59%
Trailing 12-Months
Company Description
Sanofi
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
0A2V Company Deck
0A2V Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top-line growth (9.9% FY, 13.3% Q4), robust launch performance (EUR 5.7bn from new products), significant pipeline delivery and regulatory progress, improved margins and free cash flow, plus strategic BD/M&A activity. Notable challenges include a Phase III failure for tolebrutinib, a safety case in the amlitelimab program that will require monitoring, decreased Regeneron R&D reimbursements (offset partly by higher royalties), and some uncertainty in the U.S. vaccine schedule and vaccine sales in 2026. Overall, positives (growth, profitability, launches, pipeline replenishment and balance sheet flexibility) outweigh the lowlights, though execution and regulatory/safety risks remain important to monitor.View all GB:0A2V earnings summaries0A2V Stock 12 Month Forecast
Average Price Target
$56.00
▲(22.83% Upside)